GLP1R and type 2 diabetes mellitus: Repeated measures analysis of variance can effectively use the data of each time node, fully consider the trend of each indicator over time and the possible interaction effect between them, so that the results are relatively more objective.[5,6] Based on repeated measurement analysis of variance, this study followed up for 1 year to observe the safety and effectiveness of long-acting GLP-1 receptor agonist in the treatment of overweight or obese type 2 diabetes mellitus, providing reference value for its further clinical rational use.[7,8]